GELTEX RECEIVES $2 MIL. COMMERCE DEPT. ATP GRANT
GELTEX RECEIVES $2 MIL. COMMERCE DEPT. ATP GRANT to develop nonabsorbable therapies for infectious diseases, the company announced Nov. 21. Under the three-year Advanced Technology Program grant, Waltham, Mass.-based Geltex will develop polymers that act in the gastrointestinal tract that are not absorbed into the blood stream. The company said it will target Crytosporidium parvum and human rotovirus pathogens in the initial stages of the ATP grant.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth